Evidence method
Level · gp.fundamentals.capex_revenue_ratio
270.50% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ABCL · Jun 30, 2023
AbCellera Biologics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001703057-23-000022General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
197.92% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-78.10% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-511.03% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
362.70% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
163.08% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History18 statesSelf-history eligible
Mar 31, 20220/6 normalizedLevel 3Jun 30, 20220/6 normalizedLevel 3Sep 30, 20220/6 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20235/6 normalizedLevel 3Sep 30, 20235/6 normalizedLevel 3Dec 31, 20235/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Sep 30, 20246/6 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/7 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 122.90%
- Current
- 270.50%
- Delta
- 147.59%
- Previous
- -361.41%
- Current
- 197.92%
- Delta
- 559.33%
- Previous
- -96.15%
- Current
- -78.10%
- Delta
- 18.05%
- Previous
- -532.10%
- Current
- -511.03%
- Delta
- 21.07%
- Previous
- 431.82%
- Current
- 362.70%
- Delta
- -69.12%
- Previous
- 126.92%
- Current
- 163.08%
- Delta
- 36.16%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ABCL Fundamental State →Analogous To · ABCL state analogue 2 →Transitioned To · ABCL Fundamental State →Transitioned To · ABCL CAPEX_INTENSITY_INCREASED →Transitioned To · ABCL CASH_GENERATION_INCREASED →Transitioned To · ABCL GROWTH_INCREASED →Transitioned To · ABCL PROFITABILITY_INCREASED →Transitioned To · ABCL R_AND_D_INTENSITY_DECREASED →Transitioned To · ABCL SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.